Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial

OBJECTIVE: Polyethylene glycol loxenatide (PEG-Loxe) is a novel, once-weekly glucagon-like peptide 1 receptor agonist that is approved in doses of 0.1 mg and 0.2 mg for the treatment of type 2 diabetes mellitus (T2DM). However, no clinical trials have been designed to determine the effect of 0.3 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hongyu, Chen, Qianqian, Duan, Yale, Zhao, Yue, Zhang, Xiujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909427/
https://www.ncbi.nlm.nih.gov/pubmed/36777344
http://dx.doi.org/10.3389/fendo.2023.1106868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909427/
https://www.ncbi.nlm.nih.gov/pubmed/36777344
http://dx.doi.org/10.3389/fendo.2023.1106868

Ejemplares similares